Amita Gupta, MD, MHS

Role: 
Faculty
Professor of Medicine and Public Health; Director, Division of Infectious Diseases
Amita Gupta, MD, MHS

Dr. Gupta is Director of the Division of Infectious Diseases at the Johns Hopkins School of Medicine. She is also Faculty Co-chair of the Johns Hopkins Gupta-Klinsky India Institute, and Professor of Infectious Diseases at the JH School of Medicine. She has a joint appointment in International Health at the JH Bloomberg School of Public Health.

Board certified by the American Board of Internal Medicine in infectious diseases, Dr. Gupta specializes in international public health, clinical research, and education in infectious diseases, HIV/AIDS, tuberculosis (TB), and antimicrobial resistant infections. Since 2003, her work has been focused primarily on India, where she leads several Indo-JHU research collaborations. She serves in leadership positions as Co-Chair of the Faculty Steering Committee of the Johns Hopkins Gupta-Klinsky India Institute, Center Director for the Johns Hopkins Precision Medicine Center for Excellence for COVID-19, the US chair for the Indo-US Vaccine Action Program sponsored RePORT India TB research consortium, which is funded by the US National Institutes of Health (NIH) and the government of India, Department of Biotechnology. She also serves on the global RePORT International Executive Committee, a multilateral global consortia for TB research. She is Co-principal Investigator of the NIH-funded Baltimore-Washington-India HIV and Infectious Diseases Clinical Trials Unit (BWI-CTU), and she is an active clinical investigator in multi-country trials conducted by the AIDS Clinical Trials Group (ACTG) and the International Maternal Pediatric Adolescent AIDS Trials Network (IMPAACT), and has served as protocol chair for high impact studies that have resulted in publications in The New England Journal of Medicine and The Lancet. She is Co-chair of the NIH and AmFAR funded IeDea HIV/TB Working Group and Scientific Committee co-Chair for IMPAACT TB. 

She has been awarded research grants from the NIH, CDC, UNITAID, and several philanthropic foundations to investigate infectious diseases of importance to India and beyond. In 2019, Dr. Gupta was appointed by the US Health and Human Services Secretary for a 4-year term to the NIAID Council, the chief advisory committee for National Institute of Allergy and Infectious Diseases at the U.S. National Institutes of Health. In 2020, she was invited to the Governing Board of the Indo-U.S. Science & Technology Forum

Dr. Gupta is an author of more than 200 peer-reviewed research publications and 7 book chapters on prevention and treatment of HIV, TB, and other infectious diseases, primarily in low- and middle-income settings. She has also mentored more than 35 junior scientists in India and the US to run research studies and submit their own scientific findings to peer-reviewed publications.

Dr. Gupta received an undergraduate degree from MIT, a Doctor of Medicine from Harvard Medical School, and a Master of Health Sciences in clinical investigation from JH Bloomberg School of Public Health. She completed her internal medicine training at San Francisco General Hospital-University of California, San Francisco, followed by a post-doctoral fellowships with the Epidemic Intelligence Service at the US Centers for Disease Control and Prevention (CDC, Foodborne and Diarrheal Diseases) and at the JHU School of Medicine (Infectious Diseases).

Publications on PubMed

Research Program Building and Leadership

  • 2007-present: Chair, IMPAACT P1078, A Randomized Clinical Trial to Evaluate the Safety of Immediate (antepartum-initiated) Versus Deferred Reduction in TB Incidence and Mortality Among HIV-Infected Women and Their Infants in High TB Incidence Settings
  • 2008-present: Protocol Vice-Chair of ACTG 5274, Reducing Early Mortality Among Patients with Advanced HIV Disease: A Randomized Strategy Trial Comparing the Safety and Efficacy of an Individualized Patient TB Treatment Approach to a Public Health Pre-emptive TB Treatment Approach in Resource-Limited Settings (REMEMBER)
  • 2008-2012: Co-investigator ACTG 5267, A Phase I, Safety, Tolerability, and Pharmacokinetic Interaction Study of Single-Dose TMC207 and Efavirenz in Health Volunteers
  •  2008-2012: Co-investigator ACTG 5253 Sensitivity and Specificity of Mycobacterium Tuberculosis Screening and Diagnostics in HIV-Infected Individuals
  • 2009-present: Protocol Vice Chair ACTG 5279, Phase III Clinical Trial of Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Adults with Latent Tuberculosis Infection
  • 2010: Invited by NIAID, NIH to be a part of a NIH delegation to assess scope of TB research in India. Accompanied the Deputy Director of the Division of AIDS, the Associate Director of International Health Programs, NIAID and other NIH delegates on site visits to 15 Indian institutions throughout the country
  • 2011-2012: Selected to participate in the Johns Hopkins School of Medicine’s Office in Science and Medicine (OWISM) Leadership Program for Women Faculty
  • 2012-present: Member, ACTG TB Transformative Science Group
  • 2014-present: IMPAACT TB Scientific Committee Vice-Chair
  • 2014-present: Co-investigator IMPAACT 2001 Protocol Team, PK and Safety of INH and Rifapentine in Pregnancy
  • 2014-2016: US Co-chair, NIH-India Government, Regional Prospective Observational Research in Tuberculosis (RePORT)
  • 2014-present: Co-chair PHOENIX ACTG A5300/IMPAACT 2003 feasibility study and MDR TB contact prophylaxis trial
  • 2016-present: US Chair, TB Research Consortium, RePORT India
  • 2016-present: Member, Executive Committee, RePORT International
  • 2017: Selected to participate in the Johns Hopkins Leadership Development Program (LDP)
  • 2015-present: Member, Union Interest Group in Maternal-Infant TB working group
  • 2018: Participant, Technical Consultation on Advances in Clinical Trial Design for Development of New TB Treatments, WHO Report generation
  • 2018-present: co Chair, IeDEA TB working group
  • 2019-present: NIAID Council
  • 2020-present: Governing Board Member, Indo-US Science and Technology Forum (IUSTTF)
  • 2020-present: Co-Chair, Faculty Steering Committee, Johns Hopkins Gupta-Klinsky India Institute
  • 2020-present: Center Director, Johns Hopkins Precision Medicine Center for Excellence for COVID-19

 

HIV, Gestational Diabetes and TB in Pregnancy (PraGaTHi)

Post Date: 
2023-02-27
   |   
Countries: 
   |   
Clinical Sites: 
The purpose of this study is to learn about how diabetes, TB, and HIV affect pregnant women and whether pregnancy, HIV and diabetes increase the risk of acquiring TB during pregnancy and postpartum. During pregnancy, some women will develop a form of diabetes (high blood sugar) called gestational...

Assessing prevalence and risk of lung morbidities including lung nodules and cancer using non contrast CT among PLHIV in Pune, India

Post Date: 
2022-11-25
   |   
Countries: 
   |   
Clinical Sites: 
Primary objective Determine the prevalence of pulmonary nodules, including lung cancer using NCCT. Determine the risk of pulmonary nodules, including lung cancer using NCCT. Evaluate the association of smoking, immune suppression, ART, and TB with the prevalence and risk of NCCT-diagnosed pulmonary...

A multicenter Phase II/ III double-blind, randomized, placebo controlled study to evaluate the efficacy and safety of VPM1002 in the prevention of tuberculosis (TB) recurrence in pulmonary TB patients after successful TB treatment in India.

Post Date: 
2022-05-08
   |   
Countries: 
   |   
Clinical Sites: 
To evaluate the efficacy of VPM1002 in prevention of TB recurrence in former pulmonary TB patients who have successfully completed ATT and were declared cured. Secondary Objective To evaluate the safety of VPM1002 in former TB patients who have successfully completed ATT and were declared as cured...

The Regional Prospective Observational Research In Tuberculosis (Report) India Phase II Common Protocol

Post Date: 
2022-01-10
   |   
Countries: 
   |   
Clinical Sites: 
Purpose and Scientific Aims The purpose of the RePORT India Phase II Common Protocol is to collect and utilize data and specimens for tuberculosis (TB) research, leveraging the existing infrastructure, processes, and scientific partnerships established under RePORT India consortium. The RePORT...

Innovative modelling for predicting TB treatment outcomes in global cohorts

Post Date: 
2021-12-19
Our overarching hypothesis is that clinical and laboratory risk factors for the adversity be treatment outcomes of failure, recurrence and mortality are heterogeneous and time-dependent. Precision medicine approaches supported by Machine learning techniques that overcome the limitations of...

Childhood ‘Omics’ and Mycobacterium tuberculosis-derived BiOsignatures (COMBO) for TB diagnosis

Post Date: 
2021-10-18
   |   
Countries: 
   |   
Clinical Sites: 
The overall objective of the project is to identify Mtb- and/or host-derived biosignatures in children that can achieve World Health Organization (WHO) target product profile (TPP) accuracy thresholds for a non-sputum biomarker-based triage or diagnostic test for childhood TB. We hypothesize that...

Epidemiologic Factors Associated with TB Treatment Outcomes Across Report International Consortia

Post Date: 
2021-08-12
   |   
Rationale: RePORT International was designed to enable cross-consortium data analysis. Now that a large number of consortium sites have completed participant enrollment in Common Protocol Cohort A, we can proceed with large-scale analysis of aligned RePORT data. The current study will harmonize and...

Biomarkers of Hepatotoxicity in Pregnant and Postpartum Women Living With HIV and Latent TB

Post Date: 
2021-06-21
   |   
Countries: 
   |   
Clinical Sites: 
Primary objectives: 1. Quantify INH metabolite PK in pregnant and postpartum WLWH receiving IPT, and compare INH metabolites exposures between cases and controls. 1. Identify biomarkers of hepatotoxicity in pregnant and postpartum WLWH receiving IPT. 2. Model relationships between drug metabolite...

A5362: A Phase IIc Trial of Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study

Post Date: 
2021-06-15
   |   
Countries: 
   |   
Clinical Sites: 
Primary Hypothesis A 3-month regimen of rifapentine/isoniazid/pyrazinamide/ethambutol (PHZE) with clofazimine (CFZ) dosed as 100 mg daily with a 2-week 300 mg daily loading dose (Arm 1) will demonstrate early efficacy (time to 12-week liquid culture conversion) relative to standard of care (SOC) (...

P2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs during Pregnancy and Postpartum

Post Date: 
2021-05-18
   |      |   
Clinical Sites: 
IMPAACT P1026s, the predecessor of this study, was first approved in 2003. P1026s enrolled over 1000 pregnant/postpartum women, studied the PK of more than 25 HIV and TB drugs in these women and published 27 manuscripts presenting these data. P1026s data was cited in 32% of the 76 perinatal...

The Pharmacokinetics, Safety and Acceptability of New Child-Friendly Formulations of Clofazimine and Moxifloxacin in Children Routinely Treated for Rifampicin-Resistant Tuberculosis (CATALYST)

Post Date: 
2021-04-26
   |      |   
Clinical Sites: 
PK, safety and acceptability data and practical guidance on the optimal dosing of new more child-friendly formulations of moxifloxacin and clofazimine in children are urgently needed to inform their current and future use in children with Rifampicin-Resistant TB (RR-TB). Both medications have a key...

Dynamics and immune mechanisms of QFT response in close contacts of TB cases

Post Date: 
2021-04-05
   |   
Countries: 
   |   
Clinical Sites: 
Rationale: A vaccine that prevents infection with Mycobacterium tuberculosis (Mtb) (POI vaccine) is an ideal approach to TB control. As Mtb infection (MTBI) is measured indirectly (positive tuberculin skin test (TST) or interferon gamma release assay (IGRA), prevention of IGRA conversion is the...

A Nanopore Biosensor for Leveling MTB Antigens in Blood

Post Date: 
2021-04-01
   |   
Countries: 
   |   
Clinical Sites: 
Purpose of the study: The inability to obtain diagnostically useful sputum specimens, or the inability to analyze non-sputum specimens, is a significant contributor to poor diagnostic sensitivity of current TB assays, leading to the WHO to call for the development of non-sputum-based biomarker or...

Effect of Neighborhoods and Peer Networks on substance use and violence among adolescents living with and without HIV in India

Post Date: 
2021-01-28
   |   
Countries: 
   |   
Clinical Sites: 
Purpose of the study: A strong bidirectional association exists between substance use, various forms of violence and HIV. Substance use accounts for 0.8% of the burden of disease measured in disability adjusted life years (DALYs) among adolescents in South Asia. Violence among adolescents living...

Pharmacokinetic Assessment of MDR-TB Drugs in the Treatment of TB Meningitis

Post Date: 
2020-08-23
   |      |   
Clinical Sites: 
Rationale: MDR-TBM is a devastating disease with high mortality and severe neurologic sequelae among survivors. We recognize the importance of sufficient drug concentrations at the site of infection for efficacy of anti-TB drugs and believe it is likely that drug distribution into brain and CSF...

Identification of Biomarkers That Can Predict Progression from Latent Tuberculosis Infection to Active Tuberculosis Disease

Post Date: 
2020-08-23
   |   
Countries: 
   |   
Clinical Sites: 
Purpose: The C-TRIUMPH study has identified 20 household contacts (HHC), who have progressed to active TB from its HHCs cohort (Cohort B). Immunological profiling of TB antigen induced biosignatures, profiling of transcriptional and proteomic biosignatures should provide novel insights into the...

Epidemiology and Clinical Outcomes of COVID-19 in India (ECO-19)

Post Date: 
2020-07-09
   |   
Countries: 
   |   
Clinical Sites: 
This study was terminated May 25, 2021 This is a prospective cohort study of adults with suspected COVID-19 to address key knowledge gaps in the epidemiology of disease severity and poor clinical outcomes in India. Results from this study may help clinicians in India focus limited health resources...

Tuberculosis (TB) Aftermath

Post Date: 
2020-06-05
   |   
Countries: 
   |   
Clinical Sites: 
Drs. Vidya Mave and Jonathan Golub are co-PIs and Dr. Barthwal from DY Patil Medical College is local site PI for this study. TB Aftermath seeks to provide evidence for an effective and scalable strategy targeting HHs of treated TB cases, a high priority of the NTEP. Purpose To compare the...

Mental Health Outcomes among Health Care Professionals Involved in the Treatment and Care of COVID 19 Patients in India

Post Date: 
2020-06-01
   |   
Countries: 
   |   
Clinical Sites: 
Drs. Nikhil Gupta and Nishi Suryavanshi are leading this survey project. This study is investigating the immediate impact of the COVID-19 pandemic on mental health outcomes and overall quality of life and what are the factors associated with it among Indian Health care workers. Among health care...

Hybrid Trial for Alcohol Reduction among People with TB and HIV in India

Post Date: 
2020-02-12
   |   
Countries: 
   |   
Clinical Sites: 
Dr. Geetanjali Chander is PI and Dr. Kakrani is local site PI at DY Patil Medical College for this study. The highest incidence of tuberculosis disease (TB) in the world is in India, accounting for 27% of all new cases globally, with approximately 86,000 among persons with HIV (PWH). Unhealthy...

Pages

Timing of maternal isoniazid preventive therapy on tuberculosis infection among infants exposed to HIV in low-income and middle-income settings: a secondary analysis of the TB APPRISE trial

Post Date: 
2023-09-13
   |   
Countries: 
Publication: 
Lancet Child Adolescent Health
Deferral of maternal isoniazid preventive therapy to early postpartum had no effect on infant tuberculosis acquisition in our trial population, regardless of the diagnostic test used.

Mycobacterium tuberculosis disease associates with higher HIV-1-specific antibody responses

Post Date: 
2023-05-19
   |   
Countries: 
Publication: 
Science Direct
Mycobacterium tuberculosis (Mtb) is the most common infection among people with HIV (PWH). Mtb disease-associated inflammation could affect HIV-directed immune responses in PWH. We show that HIV antibodies are broader and more potent in PWH in the presence as compared to the absence of Mtb disease...

Operational challenges undermine the WHO TB symptom screen in pregnant women in India

Post Date: 
2023-04-26
   |   
Countries: 
   |   
Clinical Sites: 
Publication: 
Open Forum Infectious Diseases
Background. Pregnancy increases both a woman's risk of developing tuberculosis (TB) and her likelihood to seek health care. A symptom screen that is effective during pregnancy would therefore be valuable. We assessed a World Health Organization (WHO)-recommended TB symptom screen in an antenatal...

Impact of undernutrition on tuberculosis treatment outcomes in India: A multicenter prospective cohort analysis by Dr. Pranay Sinha

Post Date: 
2023-04-17
   |   
Countries: 
   |   
Clinical Sites: 
Publication: 
Clinical Infectious Diseases
Abstract Background Undernutrition is the leading risk factor for tuberculosis (TB) globally. Its impact on treatment outcomes is poorly defined. Methods We conducted a prospective cohort analysis of adults with drug-sensitive pulmonary TB at 5 sites from 2015–2019. Using multivariable Poisson...

Sex Differences in TB Clinical Presentation, Drug Exposure, and Treatment Outcomes in India

Post Date: 
2023-04-01
   |   
Countries: 
Publication: 
CHEST
Background: The role of sex differences in clinical presentation, TB drug pharmacokinetic variables, and treatment outcomes is unclear. Research question: What is the effect of sex on TB disease severity, drug exposure, and treatment outcome? Study design and methods: This study was a prospective...

Factors associated with prevalent Mycobacterium tuberculosis infection and disease among adolescents and adults exposed to rifampin-resistant tuberculosis in the household

Post Date: 
2023-03-17
   |   
Countries: 
Publication: 
PLOS ONE
Background: Understanding factors associated with prevalent Mycobacterium tuberculosis infection and prevalent TB disease in household contacts of patients with drug-resistant tuberculosis (TB) may be useful for TB program staff conducting contact investigations. Methods: Using data from a cross-...

Pro-inflammatory and pro-resolving lipid mediators of inflammation in HIV: effect of aspirin intervention

Post Date: 
2023-03-01
   |   
Countries: 
Publication: 
eBioMedicine
Background: Persons with HIV (PWH) have an increased risk of cardiovascular disease (CVD) compared to HIV-seronegative individuals (SN). Inflammation contributes to this risk but the role of lipid mediators, with central roles in inflammation, in HIV infection remain to be established; further...

Characterising cause of death among people treated for drug-susceptible TB in India

Post Date: 
2023-01-12
   |   
Countries: 
Publication: 
The International Journal of Tuberculosis and Lung Disease
Annually, 1.5 million people die of TB.1 India has thehighest burden of TB,1 and in 2020, the case fatality ratio (CFR) among people with drug-susceptible TB was 4.3%.2 Even after treatment, mortality is more than two-fold higher among people with prior TB compared to the general population.3...

Predictive performance of interferon-gamma release assays and the tuberculin skin test for incident tuberculosis: an individual participant data meta-analysis

Post Date: 
2023-01-05
   |   
Countries: 
Publication: 
EClinicalMedicine
Background: Evidence on the comparative performance of purified protein derivative tuberculin skin tests (TST) and interferon-gamma release assays (IGRA) for predicting incident active tuberculosis (TB) remains conflicting. We conducted an individual participant data meta-analysis to directly...

Pharmacokinetic analysis of linezolid for multidrug resistant tuberculosis at a tertiary care centre in Mumbai, India

Post Date: 
2023-01-04
   |   
Countries: 
Publication: 
Frontiers in Pharmacology
Linezolid is an oxazolidinone used to treat multidrug-resistant tuberculosis (MDR-TB), including in the recently-endorsed shorter 6-month treatment regimens. Due to its narrow therapeutic index, linezolid is often either dose-adjusted or discontinued due to intolerance or toxicity during treatment...

Self-Reported Antiretroviral Adherence: Association with Maternal Viral Load Suppression in Postpartum Women Living with HIV-1 from Promoting Maternal and Infant Survival Everywhere (PROMISE), a Randomized Controlled Trial in Sub-Saharan Africa and India

Post Date: 
2023-01-01
   |   
Countries: 
Publication: 
Journal of Acquired Immune Deficiency Syndrome
Introduction: Optimal adherence to antiretroviral therapy (ART) is crucial to promoting maternal–infant health. Setting: Fourteen sites in 7 countries within sub-Saharan Africa and India. Methods: The multicomponent, open-label strategy PROMISE trial enrolled breastfeeding mother–infant pairs not...

The Kynurenine / Tryptophan Ratio is a Sensitive Biomarker for the Diagnosis of Pediatric Tuberculosis among Indian Children

Post Date: 
2022-12-22
   |   
Countries: 
Publication: 
Frontiers in Immunology
Objectives: Pediatric tuberculosis (TB) remains difficult to diagnose. The plasma kynurenine to tryptophan ratio (K/T ratio) is a potential biomarker for TB diagnosis and treatment response but has not been assessed in children. Methods: We performed a targeted diagnostic accuracy analysis of four...

Developing TB Vaccines for People with HIV: A Roadmap: Meeting Consensus Report

Post Date: 
2022-11-09
Publication: 
Lancet HIV
New tuberculosis vaccine candidates that are in the development pipeline need to be studied in people with HIV, who are at high risk of acquiring Mycobacterium tuberculosis infection and tuberculosis disease and tend to develop less robust vaccine-induced immune responses. To address the gaps in...

Impact of pregnancy and HIV on LTBI diagnostics and MTB-induced immune response: a cohort study in Pune, India

Post Date: 
2022-11-01
   |   
Countries: 
Publication: 
International Journal of Infectious Diseases
Background Accurate tuberculosis infection (TBI) tests are critical for pregnant women, especially those with HIV, who have a high risk of TB disease. Methods We enrolled interferon gamma release assay (IGRA)+ pregnant women with and without HIV in a longitudinal study, followed up at delivery and...

Randomized Clinical Trial of High Dose Rifampicin with or without Levofloxacin versus Standard of Care for Paediatric Tuberculous Meningitis: The TBM-KIDS Trial

Post Date: 
2022-10-29
   |   
Countries: 
Publication: 
Clinical Infectious Diseases
Background Pediatric tuberculous meningitis (TBM) commonly causes death or disability. In adults, high-dose rifampicin may reduce mortality. The role of fluoroquinolones remains unclear. There have been no antimicrobial treatment trials for pediatric TBM. Methods TBM-KIDS was a phase 2 open-label...

Willingness of Caregivers to Give Preventive Therapy to Children Living in Households of Patients with Rifampin-resistant Tuberculosis

Post Date: 
2022-10-26
   |   
Countries: 
   |   
Clinical Sites: 
Publication: 
The International Journal of Tuberculosis and Lung Disease
BACKGROUND Pediatric household contacts (HHCs) of patients with multidrug-resistant TB (MDR-TB) are at high risk of infection and active disease. Evidence of caregiver willingness to give MDR-TB preventive therapy (TPT) to children is limited. METHODS This was a cross-sectional study of HHCs of...

Whole Genome Sequencing Assessing Impact of Diabetes Mellitus on Tuberculosis Mutations and Type of Recurrence in India

Post Date: 
2022-10-06
   |   
Countries: 
Publication: 
Clinical Infectious Diseases
Dr. Vidya Mave and colleagues concluded considerable intrahost mycobacterium tuberculosis mutation rates were present at recurrence among patients with diabetes mellitus.

Clinical and Immunological Markers of Pulmonary Impairment Among People With HIV in India

Post Date: 
2022-10-06
   |   
Countries: 
Publication: 
Open Form Infectious Diseases
Dr. Akshay Gupte and team found females were 7 times more likely to have restrictive spirometry pattern and 22 times more likely to have preserved ratio impaired spirometry, compared with men.

Population Pharmacokinetic Modeling and Simulation of Rifapentine Allow Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based Dosing

Post Date: 
2022-09-20
   |   
Countries: 
Publication: 
Antimicrobial Agents and Chemotherapy
ABSTRACT The Brief Rifapentine–Isoniazid Efficacy for TB Prevention/A5279 trial demonstrated a 1-month daily regimen of rifapentine and isoniazid was noninferior to 9 months of isoniazid alone for preventing TB in persons living with HIV (PLWH). Our objective was to evaluate rifapentine...

Accuracy of Xpert MTB/RIF Ultra for the diagnosis of tuberculosis in adult patients: a retrospective cohort study

Post Date: 
2022-09-01
   |   
Countries: 
Publication: 
International Journal of Infectious Diseases
Abstract Objectives: The value of the "trace" result in Xpert Ultra for diagnosing active tuberculosis (TB) remains unclear. Our study evaluated the diagnostic accuracy of Xpert MTB/RIF Ultra (Xpert Ultra) (Cepheid, Sunnyvale, USA) over Xpert MTB/RIF (Xpert) (Cepheid, Sunnyvale, USA) and...

Pages

Matthew Murrill

Baltimore, Maryland
Matthew Murrill is an MD-PhD student in the Department of Epidemiology at the Johns Hopkins Bloomberg School of Public Health. In 2016, he was named an IDSA Education and Research Foundation Medical Scholar. After completing undergraduate studies in chemistry at Maryville College, he moved to Kolkata, India, as a Fulbright-Nehru fellow to research the sources and health effects of groundwater arsenic contamination in Eastern India with the School of Environmental Studies - Jadavpur University. He then worked for Calcutta Kids, a non-governmental organization, to establish a childhood diarrhea...

Dr. Shilpa Naik: Obstetrics and Gynecology

BJGMC-JHU Fogarty HIV-TB Program Trainee
Pune, India
I am working as an Associate Professor & Unit Incharge since 2009 in the Department of Obstetrics & Gynecology at B.J.Govt Medical College & Sassoon General Hospitals Pune. I have been managing High Risk Obstetrics and has keen interest in Critical Care Obstetrics.

Shivani Mehta

Baltimore, Maryland
Shivani Mehta is a BS/BA candidate (2018) in public health at the Johns Hopkins Krieger School of Arts and Sciences, who is working with Drs. Rupak Shivakoti and Mallika Alexander on Maternal Inflammation, Diet and Gut Microbiome in HIV: Impact on Infant Outcomes. Ms. Mehta spent June and July 2016 at BJGMC in Pune, India, working under Dr. Alexander. Awards 2016 Global Health Established Field Placement Grant 2016 Johns Hopkins Provost Undergradulate Research Award for 2016-17 From Ms. Mehta's Field Report:...

Erica Orsini, MD

Pune, India
From January 3, 2018 to February 26, 2018, Dr. Orsini worked under Drs. Vidya Mave and Amita Gupta to observe clinical rounds and provide support to the BJGMC Clinical Research Site. She also supported provides the CTRIUMPh substudy entitled “Residual Respiratory Impairment Following Pulmonary TB” and the study entitled “Antimicrobial Use and Diagnosis among Hospitalized Febrile Patients.”

Abhilash Suresh

Baltimore, Maryland
Abhilash Suresh is a BS candidate in biomedical engineering at Johns Hopkins Whiting School of Engineering (2018), who worked with Drs. Akshay Gupte and Shri Vijay Bala Yogendra Shivakumar on the C-TRIUMPH substudy on Residual Respiratory Impairment Following Pulmonary Tuberculosis. During May and June 2016 he conducted a field placement in Chennai, India, at the National Institute for Research in Tuberculosis where he worked under Dr. Shivakumar. Awards 2016 Global Health Established Field Placement Grant ...

Lubaina Arsiwala

Lubaina Arsiwala
Dr. Arsiwala is a Johns Hopkins Masters of Health Science student with a Bachelor in Dental Survey from DY Patil University School of Dentistry, Navi Mumbai, India. She visited BJGMC from June 18, 2018, to August 11, 2018, to provide support to the BJGMC Clinical Research Site. She is working with Dr. Matthew Robinson to support to ongoing studies, including “Antimicrobial Use and Diagnosis among Hospitalized Febrile Patients in Pune, India” and “Prevalence and Risk Factors for Oral Cancer among HIV-Infected Adults.” Dr. Arsiwala received funding for...

Saraniya Tharmarajah

Saraniya Tharmarajah is a public health studies student at the Johns Hopkins Krieger School of Arts and Sciences (2017). During June-July 2015, she conducted a field study placement at the National Institute of Research in Tuberculosis in Chennai, India, where she worked on the C-TRIUMPH lung health substudy. Ms. Tharmarajah is a 2015 recipient of the Global Health Established Field Placement Grant.

Pranay Vishwanath

Baltimore, Maryland
Pranay-Vishwanath
Pranay Vishwanath is a master's candidate in the field of Bioinformatics at Johns Hopkins University in Baltimore, and anticipated to graduate in Fall 2018. He is working with Drs. Amita Gupta and Jeffrey Tornheim, and is focusing on organization of data and generation/streamlining of bioinformatic pipelines for analysis of TB drug resistance assays. He received a bachelor's degree in Biotechnology at the Hong Kong University of Science & Technology in 2016.

Prarthana Vasudevan

Baltimore, Maryland
Prar Vasudevan is an international health graduate student at the Johns Hopkins School of Public Health. In Autumn 2015, she conducted a field placement in Pune, India, at BJGMC under Dr. Vidya Mave, where she worked on the study titled Maternal Inflammation, Diet and Gut Microbiome in HIV: Impact on Infant Outcomes. She is a 2015 recipient of the Global Health Established Field Placement Grant. From Prar Vasudevan's Field Report: At BJMC, I had the opportunity to make rounds in the hospital’s ART Clinic, Labor & Delivery wards, and children’s wards. I was immediately struck by the fact...

Jessica Elf, MPH, PhD

Post Doctoral Fellow
Dr. Jessica Elf was a post doctoral fellow in the Department of International Health at the Johns Hopkins School of Public Health. Her primary research focus was on the epidemiology and health impacts of tobacco use and exposure to indoor air pollution from the combustion of biomass fuels. She is a former Fogarty Fellow who lived and worked in Pune, India conducting research for her thesis project, which investigated the association between indoor air pollution and tuberculosis. She completed her undergraduate education in nutrition at the University of Florida and received an MPH and...

Jeff Tornheim, MD, MPH

Infectious Disease Fellow
Baltimore, Maryland
Jeff Tornheim, MD, MPH, is a clinical fellow in the Division of Infectious Disease here at Johns Hopkins University School of Medicine. After completing undergraduate studies in International Development and Economics at Brandeis University he moved to East Africa where he engaged in health system strengthening for returning refugees to South Sudan and worked with the Centers for Disease Control and Prevention (CDC) on the epidemiology of pneumonia and diarrhea in Western Kenya. He completed a joint MD/MPH at Mount Sinai School of Medicine, with his thesis evaluating the impact of water...

Matt Robinson, MD

Research Fellow
Baltimore, Maryland
Matthew Robinson, MD, is a research fellow in the Division of Infectious Diseases at Johns Hopkins University School of Medicine. His research focuses on the diagnosis of acute febrile illness and its implication on antimicrobial stewardship and resistance in tropical low- and middle-income countries. Matt is working with Dr. Gupta, Dr. Mave, and Dr. Cosgrove to assess the etiology of febrile illness in patients presenting to a hospital in Pune, India and to determine how diagnosis impacts antibiotic use. He is also working on a CDC-funded project to evaluate the source of antimicrobial...

Aarti Avinash Kinikar, MD: Pediatrics

BJGMC-JHU Fogarty HIV-TB Program Trainee
Pune, India
Education: MBBS (1984); DCH (1988); MD-Paediatrics (1988), DNB-Paediatrics (2003); MRCP-UK (1995). Medical Education- Grant Medical College – Mumbai University, India.

Sonya Krishnan, MD

Assistant Professor
Baltimore, Maryland
Sonya Krishnan, MD
Sonya Krishnan, MD, is Assistant Professor in the Division of Infectious Diseases at Johns Hopkins University School of Medicine. Her research interests include host biomarkers of HIV/TB and TB outcomes with particular interest in understanding inflammation pathways, their impacts and potential therapies. Dr. Krishnan grew up in Minnesota and completed her undergraduate studies at Carleton College, becoming involved in HIV research while studying abroad in Tanzania. After college she spent two years at the NIH studying predictors of IRIS as well as inflammatory markers in HIV-infected elite...

Amit Kale, MS: Orthopedics

BJGMC-JHU Fogarty HIV-TB Program Trainee
Pune, India
I am working as associate professor in orthopedics. Currently, I am conducting various drug trials for rheumatoid arthritis.

Anita Basavaraj, MD: Gastroenterology

BJGMC-JHU Fogarty HIV-TB Program Trainee
Pune, India
Dr Anita Basavaraj has done her MBBS from Nagpur University with Honors in Surgery (1987). Thereafter she did her MD in Medicine (1990) and her Diplomat of National Board (D.N.B.) in 1992.She has done her post graduate Diploma in geriatric Medicine (P.G.D.G.M.) winning the university Gold Medal by virtue of standing first in the country (2012), which is a distant education venture run by Indira Gandhi National Open University (IGNOU).

Geeta Shrikar Pardeshi, MD: Preventive and Social Medicine

BJGMC-JHU Fogarty HIV-TB Program Trainee
Pune, India
I have led research projects related to Reproductive and Child Health, Sanitation and Infectious diseases. As part of the BJGMC JHU Fogarty training program in HIV-TB, I have research interest in TB epidemiology. I am interested in studying the association of co-morbidities with clinical presentation and treatment outcomes in tuberculosis.

Sunita Girish, PhD: Medical Biochemistry

BJGMC-JHU Fogarty HIV-TB Program Trainee
Pune, India
Education: Ph.D, Pune University, 2005 (Medical Biochemistry) title “Antioxidant Status in Leprosy.” Overview: How to improve health systems to combat various infectious diseases like Leprosy, Tuberculosis and HIV in developing countries, is a research and policy issue that affects many aspects of public health. My research interests include further to understand molecular level changes in cystic fibrosis which is under diagnosed .My interests also involve innovations in molecular techniques dealing with infectious diseases, help governments in developing countries to improve and modify drug...

Sangita Shelke, MD: Preventive and Social Medicine; Diplomas in Nutrition, Hospital Administration, Psychological counseling

BJGMC-JHU Fogarty HIV-TB Program Trainee
Pune, India
Indeed TB is a social disease with so many social problems especially the women suffering from TB/HIV undergoes a pathetic life situation. Women are silent suffers, of both HIV and TB in male dominated society of India. My ultimate desire is if I can make a difference in the lives of these silent suffers.

Dr. Smita Deshpande: Microbiology

BJGMC-JHU Fogarty HIV-TB Program Trainee
My research interests have been: Rapid diagnostic methods for Acute pyogenic meningitis, Diagnosis of enteric fever , Role of Methicillin resistance Staph aureus in infections, Molecular diagnosis of Leptospirosis, Rapid diagnosis of MDR-TB by REMA ( Resasurine Micro titre Plate Assay)and by Line Probe Assay.

Pages

FE Cardiology Summit, Cardiovascular Diabetes – A Growing Concern.

Post Date: 
2021-10-05
Amita Gupta joined the FE Cardiology Summit to discuss the intersection of cardiovascular disease, diabetes, and COVID-19. Check out what she has to say

250,000 patients to benefit from free access to short-course TB prevention treatment across seven countries

Post Date: 
2023-03-30
Source: 
Unitaid
Amita Gupta, MD, MHS
The patient courses will include the three-month 3HP regimen, and the even shorter 1HP, that is only taken for 28 days. This contribution is part of the Consortium’s ongoing efforts to end TB and improve global health outcomes.

Monkeypox: ‘No plans yet to get vaccine,’ says health ministry

Post Date: 
2022-07-26
Source: 
The Hindustan Times
Amita Gupta headshot
Dr. Amita Gupta spoke to the Hindustan Times about the monkeypox outbreak. “Currently mass vaccination is not required. Instead, priority is recommended for contacts of cases..."

COVID virus can evolve in animals, spawn variants that can jump back to humans: Scientists

Post Date: 
2022-04-28
Source: 
Business Today
decorative: covid virus
Last week, the Centers for Disease Control and Prevention (CDC) confirmed that at least four people in Michigan, US, were infected with a version of the coronavirus observed mostly in minks during the first year of the pandemic.

CAB Spotlight - Vijaya Jori

Post Date: 
2022-04-01
Source: 
ACTG Newsletter
Vijaya Jori
Community Advisory Boards are key members of research programs. The ACTG Newsletter features Vijaya Jori of the JHU-BJGMC CAB!

Amita Gupta Named Director of Johns Hopkins Medicine’s Division of Infectious Diseases

Post Date: 
2022-02-04
Source: 
hopkinsmedicine.org
Dr. Amita Gupta
Congratulations on this amazing achievement! Dr.. Amita Gupta will be our next director of the Division of Infectious Diseases effective immediately.

Gupta Named Director of the Division of Infectious Diseases

Post Date: 
2022-01-24
Dr. Amita Gupta
Congratulation on this amazing achievement! Dr.. Amita Gupta will be our next director of the Division of Infectious Diseases effective immediately.

Fact check: False claim that pumpkin seeds can treat worms and parasites in the body

Post Date: 
2022-01-04
Source: 
USATODAY
Dr. Amita Gupta: "There is no human clinical trial that has shown that pumpkin seeds are an effective treatment for parasites or worms."

Dashboards and trackers: Covid-19 pandemic made data new normal

Post Date: 
2021-11-30
Source: 
Business Standard
Lack of reliable numbers to accurately portray the Covid19 pandemic may result in the dangerous equation ‘’no data is equal to no problem.’

Covid-19 pandemic and the unprecedented rise of data

Post Date: 
2021-11-29
Source: 
Business Standard
Dr. Amita Gupta
Enormous amounts of data have been generated and analysed during the Covid-19 pandemic around the world. India has been there, too, and how.

The Growing Threat of Antimicrobial Resistance in India

Post Date: 
2021-11-12
Source: 
contagionlive.com
Dr. Amita Gupta
India is the world’s leading consumer of antibiotics, and Amita Gupta, MD, is researching how the country can best mitigate the spread of antimicrobial resistance.

India Revises National TB Prevention Guidelines Using Findings from Indo-JHU Research 

Post Date: 
2021-08-31
Source: 
CCGHE
TB graphic
“If we can screen patients early and get their household contacts on preventive therapy, we have an opportunity to stop the chain of this horrible disease.”

Global Coronavirus Pandemic

Post Date: 
2021-07-16
Source: 
The World Tonight. Black News Channel
The World Tonight, Black News Channe l: Dr. Amita Gupta discusses the challenges associated with COVID vaccination in low and middle income countries.

Johns Hopkins Students and Faculty Members Confront India’s COVID-19 Crisis

Post Date: 
2021-07-08
Source: 
Johns Hopkins Medicine
Dr. Amita Gupta
Dr. Amita Gupta: “If India is not safe, the world’s not safe. COVID anywhere affects us everywhere, and so we can’t lay down the guard.”

Proceedings of IMPAACT Annual Meeting 2021 Now Online

Post Date: 
2021-06-30
Source: 
impaactannualmeetings.org
IMPAACT
View video presentations from this year’s annual meeting, highlighting the latest updates and exciting science in the field.

7 Lessons We’ve Learned From This Pandemic to Remember for the Next One

Post Date: 
2021-06-22
Source: 
Self
Dr. Amita Gupta
Dr. Amita Gupta: "We aren’t going to be able to treat our way out of disease. We need to prevent more infections from happening."

Why India’s COVID-19 data is vastly undercounted

Post Date: 
2021-06-22
Source: 
Gruntstuff
Dr. Amita Gupta: “We care from a humanitarian perspective, a public well being perspective and a well being safety perspective.”

A Blueprint for Preventing Another Pandemic

Post Date: 
2021-06-22
Source: 
Time
Dr. Amita Gupta
TIME polled 73 experts on how to mitigate the next health crisis. The responses offer a plan to build a more prepared world.

Ask The Doctor

Post Date: 
2021-06-22
Source: 
Twitter
Vikram Chandra, Founder, Editorji Technologies interviews Dr Amita Gupta, Dr Vincent Rajkumar, and Dr Aju Mathew.

Global crisis in the making

Post Date: 
2021-06-10
Source: 
Daily News
As countries around the world airlift oxygen, vaccines and medical supplies to India, they are also closing their borders to the world’s second most populous country.

India COVID-19 Outbreak Could 'Spread Around The World,' Expert Warns

Post Date: 
2021-05-13
Source: 
International Business Times
Dr. Amita Gupta
"There was essentially a lot of relaxation of rules," Dr. Amita Gupta, an infectious disease specialist at the Johns Hopkins Bloomberg School of Public Health.

Pages